You are here: Welcome to the MPKB » Welcome to the MPKB » Symptoms » Skin conditions
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Last revisionBoth sides next revision
home:symptoms:skin [09.03.2012] – paulalberthome:symptoms:skin [08.23.2017] – [Immune response and skin disease] sallieq
Line 26: Line 26:
 ===== Immune response and skin disease ===== ===== Immune response and skin disease =====
  
-In human skin antimicrobial peptide (AMP) are produced mainly by keratinocytes, neutrophils, sebocytes or sweat glands and are either expressed constantly or after an inflammatory stimulus.(({{pubmed>long:18782030}})) As Schittek //et al.// explain, in several human skin diseasess, there is an inverse correlation between severity of the disease and the level of AMP production. Skin lesions of patients with atopic dermatitis show a diminished expression of the beta-defensins and the cathelicidin LL-37 (both of which are strongly expressed by the Vitamin D Receptor). Furthermore, these patients have a reduced amount of the AMP dermcidin in their sweat which correlates with an impaired innate defense of human skin //in vivo//. In addition, decreased levels of AMPs are associated with burns and chronic wounds. In contrast, overexpression of AMPs can lead to increased protection against skin infections as seen in patients with psoriasis and rosacea, inflammatory skin-diseases which rarely result in superinfection. In other skin diseases, e.g. in patients with acne vulgaris, increased levels of AMPs are often found in inflamed or infected skin areas indicating a role of these peptides in the protection from infection. These data indicate that AMPs have a therapeutical potential as topical anti-infectives in several skin diseases.(({{pubmed>long:18782030}}))+In human skin antimicrobial peptide (AMP) are produced mainly by keratinocytes, neutrophils, sebocytes or sweat glands and are either expressed constantly or after an inflammatory stimulus.(({{pubmed>long:18782030}})) As Schittek //et al.// explain, in several human skin diseases, there is an inverse correlation between severity of the disease and the level of AMP production. Skin lesions of patients with atopic dermatitis show a diminished expression of the beta-defensins and the cathelicidin LL-37 (both of which are strongly expressed by the Vitamin D Receptor). Furthermore, these patients have a reduced amount of the AMP dermcidin in their sweat which correlates with an impaired innate defense of human skin //in vivo//. In addition, decreased levels of AMPs are associated with burns and chronic wounds. In contrast, overexpression of AMPs can lead to increased protection against skin infections as seen in patients with psoriasis and rosacea, inflammatory skin-diseases which rarely result in superinfection. In other skin diseases, e.g. in patients with acne vulgaris, increased levels of AMPs are often found in inflamed or infected skin areas indicating a role of these peptides in the protection from infection. These data indicate that AMPs have a therapeutical potential as topical anti-infectives in several skin diseases.(({{pubmed>long:18782030}}))
  
  
Line 207: Line 207:
 All this has made me contact the skin and cancer foundation of Australia where I originally went and got my diagnosis of sarcoidosis 8 years ago. I spoke to them and told them about all this. It flew over there heads but they are willing to see me because my case was very interesting for them at the time and I think they want to know how all this stuff works because I'm the living proof of the MP working. All this has made me contact the skin and cancer foundation of Australia where I originally went and got my diagnosis of sarcoidosis 8 years ago. I spoke to them and told them about all this. It flew over there heads but they are willing to see me because my case was very interesting for them at the time and I think they want to know how all this stuff works because I'm the living proof of the MP working.
  
-//**Simon Elrahi**, MarshallProtocol.com//</blockquote>+//**Simonc**, MarshallProtocol.com//</blockquote>
  
  
Line 268: Line 268:
 ===== Notes and comments ===== ===== Notes and comments =====
  
 +
 +<blockquote>
 +Curr Pharm Des. 2006;12(29):3787-98.
 +Functional genome and proteome analyses of cutaneous autoimmune diseases.
 +Trcka J, Kunz M.
 +Source
 +Department of Dermatology and Venerology, University of Rostock, 18055 Rostock, Germany.
 +Abstract
 +The use of functional genomics and proteomics technologies has dramatically increased through recent years with a special emphasis on cancer biology. However, a series of more recent reports has also addressed inflammatory diseases. These included studies on different autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus, and systemic sclerosis. Gene and protein expression profiles from these studies have emphasized the role of cytokines, chemokines, and apoptosis-related molecules for the pathogenesis of autoimmune diseases. Much less is known about gene and protein patterns of these diseases in dermatology. Here we provide an overview on current knowledge about genomics and proteomics analyses of cutaneous autoimmune diseases. These diseases include psoriasis, lupus erythematosus, systemic sclerosis, vitiligo, and alopecia areata. The presented findings not only provide deeper insights into the pathogenesis of each individual disease but also show overlapping gene patterns suggestive for common pathogenic mechanisms. However, many open questions remain to be resolved since data about local gene expression pattern in affected tissues are still scarce.
 +PMID: 17073677
 +</blockquote>
 ===== References ===== ===== References =====
home/symptoms/skin.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.